1-2 of 2
Maki Yamamoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Aref Al-Kali, Antoine Saliba, Cecilia Y. Arana Yi, James M. Foran, Yasushi Tanoue, Maki Yamamoto, Joachim Gullbo, Guillermo Garcia-Manero
Journal: Blood
Blood (2023) 142 (Supplement 1): 3249.
https://doi.org/10.1182/blood-2023-173496
Published: 2023
Journal Articles

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

Hisayuki Yokoyama, Koji Ando, Noriko Fukuhara, Hiroatsu Iida, Suguru Fukuhara, Hiroshi Miyake, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Akio Mizutani, Daisuke Morishita, Kunihiko Takeyama, Toshio Shimizu, Noboru Yamamoto
Journal: Blood
Blood (2022) 140 (Supplement 1): 6211–6212.
https://doi.org/10.1182/blood-2022-157241
Published: 2022